Navigation Links
Innolife Pharma Inc. acquires rights to breakthrough in non-narcotic chronic pain treatment

Relief soon to be widely available for chronic pain sufferers.

MARKHAM, ON, May 20 /PRNewswire-FirstCall/ - Innolife Pharma, Inc. (Other OTC:INNP.PK - News) is pleased to announce that it has acquired North American licensing rights to the Natural Pain Relief Center non-narcotic proprietary breakthrough in the treatment of chronic pain.

Today, one in five Americans suffer with chronic pain (~ 60 million adults) spending approximately $120 Billion a year and the aging baby boomers have reported in surveys more aches and pains than any previous generation.

New Medical Finding with Brain Scans and Functional MRI's

Modern Brain Imaging has revealed that most chronic pain is the result of the brain's inability to turn off pain messages from the body. In chronic pain the brain simply is not producing and releasing enough natural pain killers (such as endorphins) to stop the person's suffering. These new medical findings show that chronic pain sufferers from headaches, migraines, fibromyalgia, back pain, sciatica, arthritis or a combination of all of them, are caused by a low level of Natural Pain Killer's (such as Endorphins and others) in the brain, as compared to people without chronic pain.

Over three years of in-clinic testing showed that this breakthrough all-natural program relieved significant chronic pain in 8 out of 10 people and with sustainable results. This non-narcotic, combination treatment has been receiving accolades from chronic pain sufferers with major improvement in mood and energy and dramatic decreases in pain levels, allowing a return to normal life function.

Innolife Pharma Inc. has an aggressive growth plan in place with a projected target of 95 licensed clinics in 3 years with projected top line annual revenue in excess of $30 million and a projected bottom line profit of over $12 million annually (40+%).

With the aging demographic, chronic pain is becoming a larger and larger international epidemic. Innolife Pharma Inc. is positioned to be the leading service provider in this segment - with a business model that is designed to provide excellent operating margins and tremendous growth for many years to come.

About Innolife Pharma Inc.

Innolife Pharma Inc. (PINKSHEETS: INNP) is a small publicly traded specialty multi-discipline medical group focusing on licensing the Natural Pain Relief Center all-natural proprietary breakthrough in the treatment of chronic pain.


This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

SOURCE Innolife Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology: